Ovulation induction treatment and risk of borderline ovarian tumors

Cusidó, Maite; Fábregas, R.; Pere, Barris S; Escayola, Cecilia; Barri, P. N.

doi:10.1080/09513590701350341

Cited by 39 publications

(28 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We found elevated risk of borderline ovarian tumors in women treated with ART, in line with two previous studies (7, 45), but in contrast to a further three (41, 46, 47). In our study, we could not observe difference in risk among nulliparous and parous women.…”

Section: Discussionsupporting

confidence: 92%

Cancer Risk in Women Treated with Fertility Drugs According to Parity Status—A Registry-based Cohort Study

Reigstad

Storeng

Myklebust

et al. 2017

Cancer Epidemiology, Biomarkers &Amp; Prevention

View full text Add to dashboard Cite

Background Long-term safety of assisted reproductive techniques (ART) is of interest as use is increasing. Cancer risk is known to be affected by parity. This study examined risk of cancer after fertility treatment, stratified by women’s parity. Methods Data was obtained on all women (n=1 353 724) born in Norway between 1960–1996. Drug exposure data (2004–2014) was obtained from the Norwegian Prescription Database [drugs used in ART and clomiphene citrate (CC)]. The Medical Birth Registry of Norway provided parity status. Hazard ratios were calculated for all site cancer, breast, cervical, endometrial, ovarian, colorectal, central nervous system, thyroid cancer and malignant melanoma. Results In 12 354 392 person-years of follow-up, 20 128 women were diagnosed with cancer. All-site cancer risk was (1.14, 1.03–1.26) and (1.10, 0.98–1.23) following CC and ART exposure respectively. For ovarian cancer, a stronger association was observed for both exposures in nulliparous (HR 2.49, 1.30–4.78, and HR 1.62, 0.78–3.35) versus parous women (HR 1.37, 0.64–2.96, and HR 0.87, 0.33–2.27). Elevated risk of endometrial cancers was observed for CC exposure in nulliparous women (4.59, 2.68–7.84 vs. 1.44, 0.63–3.31). Risk was elevated for breast cancer in parous women exposed to CC (1.26, 1.03–1.54) and among nulliparous women after ART treatment (2.19, 1.08–4.44). Conclusion CC appears associated with increased risk of ovarian and endometrial cancer. Elevations in risks of breast and thyroid cancer were less consistent across type of drug exposure and parity. Impact Continued monitoring of fertility treatments is warranted.

show abstract

Section: Discussionsupporting

confidence: 92%

Cancer Risk in Women Treated with Fertility Drugs According to Parity Status—A Registry-based Cohort Study

Reigstad

Storeng

Myklebust

et al. 2017

Cancer Epidemiology, Biomarkers &Amp; Prevention

View full text Add to dashboard Cite

show abstract

“…The management of such patients has been a controversial task, particularly since the use of fertility drugs was identified as a risk factor for the development of ovarian neoplasms in some studies [7,8] ; however, other studies have not been able to confirm this association [9,10] . A meta-analysis of all the available literature found that infertility treatment did not independently increase the risk of ovarian neoplasm; however, infertility itself was an independent risk factor for this disorder [11] .…”

mentioning

confidence: 96%

Clinical Recommendation on Fertility Preservation in Borderline Ovarian Neoplasm: Ovarian Stimulation and Oocyte Retrieval after Conservative Surgery

Denschlag

Wolff²,

Amant³

et al. 2010

Gynecol Obstet Invest

View full text Add to dashboard Cite

Aim: To evaluate safety and fertility outcome after assisted conception in patients who were treated conservatively for a borderline ovarian tumor (BOT). Methods: A systematic literature review using Medline was conducted. From all the relevant case series the following information was obtained for each reported patient: primary diagnosis; disease stage; surgical treatment; duration of follow-up; incidence of recurrence; current disease status; the number of controlled ovarian stimulation cycles and/or oocyte retrievals, and successful pregnancies. Results: Overall 588 articles were screened, of which finally 15 reports including 62 patients met the inclusion criteria. Within a median follow-up duration of 52 months in this small group of patients, overall 12 patients (19.4%) had recurrences, and those recurrences were again successfully treated by surgery in 11 patients. In terms of assisted reproductive outcome, in our series overall 152 ovarian stimulation cycles as well as 135 oocyte retrievals were performed with a baby-take-home rate of 28.3% per stimulated cycle. Conclusion: It is mandatory to counsel all patients with a history of BOT who are seeking treatment for infertility that, due to the limited data, it is unclear whether assisted reproductive techniques are associated with an increased risk of recurrence.

show abstract

“…Other studies have reported an increased risk of ovarian cancer in women treated with fertility drugs [15-17,21,22,42,44,46,49-51]. Finally some studies have reported an increased risk especially for borderline ovarian tumors [16,21,22,36,42,49,50]. …”

Section: Discussionmentioning

confidence: 99%

Fertility drugs, reproductive strategies and ovarian cancer risk

Tomao

Russo

Spinelli

et al. 2014

Journal of Ovarian Research

View full text Add to dashboard Cite

Several adverse effects have been related to infertility treatments, such as cancer development. In particular, the relationship between infertility, reproductive strategies, and risk of gynecological cancers has aroused much interest in recent years. The evaluation of cancer risk among women treated for infertility is very complex, mainly because of many factors that can contribute to occurrence of cancer in these patients (including parity status). This article addresses the possible association between the use of fertility treatments and the risk of ovarian cancer, through a scrupulous search of the literature published thus far in this field. Our principal objective was to give more conclusive answers on the question whether the use of fertility drug significantly increases ovarian cancer risk. Our analysis focused on the different types of drugs and different treatment schedules used. This study provides additional insights regarding the long-term relationships between fertility drugs and risk of ovarian cancer.

show abstract

Ovulation induction treatment and risk of borderline ovarian tumors

Abstract: Our series produced no evidence that ovulation induction treatment predisposes women to the development of borderline ovarian tumors.

Cited by 39 publications

References 14 publications

Cancer Risk in Women Treated with Fertility Drugs According to Parity Status—A Registry-based Cohort Study

Cancer Risk in Women Treated with Fertility Drugs According to Parity Status—A Registry-based Cohort Study

Clinical Recommendation on Fertility Preservation in Borderline Ovarian Neoplasm: Ovarian Stimulation and Oocyte Retrieval after Conservative Surgery

Fertility drugs, reproductive strategies and ovarian cancer risk

Contact Info

Product

Resources

About